drugset / Trial / NCT05199571
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.
Timeline
- Start
- 2022-07-22
- Primary completion
- 2025-02-13
- Completion
- 2025-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ofatumumab | Monoclonal antibody | 20 mg | Subcutaneous |